Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study.

ABSTRACT:

Background

Statin treatment is a potent lipid-lowering therapy associated with decreased cardiovascular risk and mortality. Recent studies including the PARADIGM trial have demonstrated the impact of statins on promoting calcified coronary plaque.

Hypothesis

The degree of systemic inflammation impacts the amount of increase in coronary plaque calcification over 2 years of statin treatment.

Methods

A subgroup of 142 participants was analyzed from the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study (NCT01212900), who were on statin treatment and underwent cardiac computed tomography angiography (CCTA) at baseline and 2-year follow-up. This cohort was stratified by baseline median levels of high-sensitivity hs-CRP and analyzed

SUBMITTER: Scott C 

PROVIDER: S-EPMC9175258 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature